Loading...
Jiangsu Recbio Technology Co., Ltd.
2179.HK•HKSE
Healthcare
Biotechnology
HK$7.80
HK$-0.30(-3.70%)
Jiangsu Recbio Technology Co., Ltd. (2179.HK) Financial Performance & Income Statement Overview
Review Jiangsu Recbio Technology Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-11.10%
↓ 11.10%
Operating Income Growth
7.43%
↑ 7.43%
Net Income Growth
1.67%
↑ 1.67%
Operating Cash Flow Growth
27.15%
↑ 27.15%
Operating Margin
-2117.56%
↓ 2117.56%
Gross Margin
59.04%
↑ 59.04%
Net Profit Margin
-2082.54%
↓ 2082.54%
ROE
-82.34%
↓ 82.34%
ROIC
-51.95%
↓ 51.95%
Jiangsu Recbio Technology Co., Ltd. (2179.HK) Income Statement & Financial Overview
Review Jiangsu Recbio Technology Co., Ltd.'s (2179.HK) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $4.69M | $4.69M | $8.81M | $8.81M |
| Cost of Revenue | $1.005M | $1.005M | $4.53M | $4.53M |
| Gross Profit | $3.69M | $3.69M | $4.29M | $4.29M |
| Gross Profit Ratio | $0.79 | $0.79 | $0.49 | $0.49 |
| R&D Expenses | $135.45M | $135.45M | $102.61M | $102.61M |
| SG&A Expenses | $27.72M | $27.72M | $28.11M | $28.11M |
| Operating Expenses | $163.17M | $163.17M | $130.72M | $130.72M |
| Total Costs & Expenses | $164.18M | $164.18M | $135.25M | $135.25M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $11.97M | $17.61M | $17.61M | $17.61M |
| EBITDA | -$147.52M | -$141.88M | -$108.83M | -$108.83M |
| EBITDA Ratio | -$31.44 | -$30.24 | -$12.35 | -$12.35 |
| Operating Income | -$159.49M | -$159.49M | -$126.44M | -$126.44M |
| Operating Income Ratio | -$33.99 | -$33.99 | -$14.35 | -$14.35 |
| Other Income/Expenses (Net) | $3.35M | $3.35M | $1.62M | $1.62M |
| Income Before Tax | -$156.13M | -$156.13M | -$124.82M | -$124.82M |
| Income Before Tax Ratio | -$33.27 | -$33.27 | -$14.17 | -$14.17 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$250500.00 |
| Net Income | -$156.63M | -$156.63M | -$124.57M | -$124.57M |
| Net Income Ratio | -$33.38 | -$33.38 | -$14.14 | -$14.14 |
| EPS | -$0.32 | -$0.32 | -$0.26 | -$0.26 |
| Diluted EPS | -$0.32 | -$0.32 | -$0.26 | -$0.26 |
| Weighted Avg Shares Outstanding | $485.82M | $485.82M | $478.91M | $478.91M |
| Weighted Avg Shares Outstanding (Diluted) | $478.18M | $478.18M | $478.91M | $478.91M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan